P4INVEST
ActiveP4INVEST has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €632k and a net result of €104k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 15% of 2315 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
66
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability62▼-25
Solvency37▼-13
Growth78=
Track record100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40k at 30 days acceptable
Liquidity tight (current ratio 1.15 against 2.41 in 2024; short-term debt: 23% and cash: 6.5% of total assets), and 88% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
12%
Return on assets
2%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 15% of 2315 sector peers (2025).
NBB · sector comparisonPosition among 2315 sector peers
Solvency
better than 15%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 13-07-2026, 18 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
18 d early
2024
27 d late
2023
20 d late
2022
31 d late
2021
29 d late
2020
16 d late
2019
45 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€104k▼ 78.2%
2024 · €477k
2018: €-57k
2019: €-422k
2020: €152k
2021: €341k
2022: €380k
2023: €364k
2024: €477k
2018 → 2025
Working capital
€184k▼ 74.6%
2024 · €727k
2018: €-50k
2019: €-294k
2020: €-109k
2021: €228k
2022: €416k
2023: €657k
2024: €727k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-84k-€275k€610k▲ 122%€808k▲ 32.5%€632k▼ 21.8%
Operating result€388k-€434k▲ 11.9%€539k▲ 24.1%€690k▲ 28.1%€215k▼ 68.9%
Net result€341k-€380k▲ 11.5%€364k▼ 4.3%€477k▲ 31.1%€104k▼ 78.2%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 69% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €5.28M
Fixed assets
€3.88M▲ 89.9%
Current assets
€1.40M▲ 12.4%
Equity and liabilities €5.28M
Equity
€632k▼ 21.8%
Debt
€4.65M▲ 87.4%
The debt ratio rises from 75.4% to 88.0%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€346k▼
2024 · €809k
Cash flow
€235k▼
2024 · €596k
Solvency
12.0%▼
2024 · 24.6%
Current ratio
1.15▼
2024 · 2.41
Quick ratio
0.64▼
2024 · 1.02
Debt / equity
7.36▲
2024 · 3.07
ROE
16.4%▼
2024 · 59.1%
ROA
2.0%▼
2024 · 14.5%
Interest coverage
4.86▼
2024 · 14.15
Debt
€4.65M▲
2024 · €2.48M
Debt ≤ 1 year
€1.21M▲
2024 · €516k
Debt > 1 year
€3.42M▲
2024 · €1.89M
Income taxes
€42k▼
2024 · €164k
Staff costs
€839k▲
2024 · €744k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€3.29M€5.28M▲
Fixed assets21/28€2.05M€3.88M▲
Tangible fixed assets22/27€2.04M€1.98M▼
Land and buildings22€1.78M€1.71M▼
Plant, machinery and equipment23€230k€215k▼
Furniture and vehicles24€36k€60k▲
Financial fixed assets28€2k€1.90M▲
Current assets29/58€1.24M€1.40M▲
Stocks and contracts in progress3€714k€616k▼
Stocks30/36€714k€616k▼
Amounts receivable within one year40/41€211k€397k▲
Trade receivables40€211k€289k▲
Other amounts receivable41€410€108k▲
Cash at bank and in hand54/58€317k€341k▲
Deferred charges and accrued income490/1€860€44k▲
Equity and liabilities
Total equity and liabilities10/49€3.29M€5.28M▲
Equity10/15€808k€632k▼
Contributions10/11€20k€20k=
Reserves13€788k€612k▼
Distributable reserves133€788k€612k▼
Profit (loss) carried forward14€0€0=
Amounts payable17/49€2.48M€4.65M▲
Amounts payable after more than one year17€1.89M€3.42M▲
Financial debts170/4€1.89M€3.42M▲
Amounts payable within one year42/48€516k€1.21M▲
Current portion of amounts payable after more than one year42€131k€262k▲
Trade debts44€207k€706k▲
Suppliers440/4€207k€706k▲
Advances received on contracts in progress46-€20k
Taxes, remuneration and social security45€138k€181k▲
Taxes450/3€37k€55k▲
Remuneration and social security454/9€101k€126k▲
Other amounts payable47/48€40k€44k▲
Accrued charges and deferred income492/3€75k€16k▼
Income statement
Code20242025
Remuneration, social security and pensions62€744k€839k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€119k€131k▲
Other operating charges640/8€12k€12k▼
Gross operating margin9900€1.57M€1.20M▼
Operating profit (loss)9901€690k€215k▼
Financial income75/76B€8k€2k▼
Recurring financial income75€8k€2k▼
Financial charges65/66B€57k€71k▲
Recurring financial charges65€57k€71k▲
Profit (loss) for the period before taxes9903€641k€145k▼
Income taxes67/77€164k€42k▼
Profit (loss) for the period9904€477k€104k▼
Profit (loss) for the period to be appropriated9905€477k€104k▼
Appropriation of the result
Profit (loss) to be appropriated9906€477k€104k▼
Transfer from equity791/2€235k€235k=
Transfer to equity691/2€434k€59k▼
To other reserves6921€434k€59k▼
Profit to be distributed694/7€279k€280k▲
Return on contributions (dividend)694€235k€235k=
Employees696€0-
Other beneficiaries697€44k€45k▲
Social balance
Average headcount (FTE)908715.315.4▲
The notes to these accounts (17 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
13-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
27-08
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 27 days late
2024
31-12
Financial
Highest result since 2018net €477k ▲31.1%
Operating result €690k, net result €477k, both a record.
20-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 20 days late
2023
31-12
Financial
Equity above €500kEq €610k ▲122%
4 profitable years in a row build equity to €610k.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 31 days late
2022
31-12
Financial
Equity above €200kEq €275k
3 profitable years in a row build equity to €275k.
29-08
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 29 days late
2021
31-12
Financial
Liquidity doublescurrent ratio 1.60
Current ratio from 0.76 to 1.60; short-term debt falls from €459k to €382k.
16-08
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 16 days late
2020
31-12
Financial
Back to profitnet €152k
Net result €152k after 2 loss-making years.
14-09
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 45 days late
2019
31-12
Financial
Weakest financial yearnet €-422k
Net result drops to €-422k, the lowest in the series; recovery starts the following year.
16-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
23-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Nandrin · 1 establishment unit since 2017
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Route du Condroz 3224550 NandrinGround area
1,896 m²
Building footprint
655 m²
Parcel 61043B0005/00H000, Wallonia. Linked by address, not a title deed.
1 establishment unit
P4INVEST
since 20172.262.806.694
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 61043B0005/00H000 | Wallonia | 1,896 m² | 1 · 655 m² | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
KINEACU-MED
BE 0822.760.730
Vorst · Eq €634k
KINESITHERAPIE VERFAILLIE
BE 0806.510.953
Comines-Warneton · Eq €624k
DR. PASCAL WERNAERS
BE 0821.921.382
Tienen · Eq €643k
KINEFLEX
BE 0459.715.959
Kortenaken · Eq €598k
ORTHO BINGEN-HARIGA
BE 0503.779.396
Namur · Eq €677k
Of 12,690 companies in sector 86951 we hold annual accounts for 2,140. 898 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded30-03-2017
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
86905Human health activities
86951Physiotherapy
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
46389Wholesale of other food products
47279Other retail sale of food
47299Retail trade
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
96022Beauty treatment
96220Beauty care and other beauty treatments
Sources
Crossroads Bank for EnterprisesNational Bank · 9 filingsAddress and cadastre registers
Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.